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MaOBJECTIVES The goal of this study was to assess the safety and tolerability of omecamtiv mecarbil treatment during
symptom-limited exercise in patients with ischemic cardiomyopathy and angina. These patients may have increased
vulnerability to prolongation of the systolic ejection time.
BACKGROUND Omecamtiv mecarbil is a selective cardiac myosin activator that augments cardiac contractility in
patients with systolic heart failure through a dose-dependent increase in systolic ejection time.
METHODS In this double-blind, placebo-controlled study, patients with chronic heart failure were randomized 2:1
to receive omecamtiv mecarbil or placebo in 2 sequential cohorts of escalating doses designed to achieve plasma
concentrations previously shown to increase systolic function. Patients underwent 2 symptom-limited exercise treadmill
tests (ETTs) at baseline (ETT1 and ETT2) and again before the end of a 20-h infusion of omecamtiv mecarbil (ETT3).
RESULTS The primary pre-deﬁned safety endpoint (i.e., the proportion of patients who stopped ETT3 because of angina
at a stage earlier than baseline) was observed in 1 patient receiving placebo and none receiving omecamtiv mecarbil. No
dose-dependent differences emerged in the proportion of patients stopping ETT3 for any reason or in the pattern of
adverse events.
CONCLUSIONS Doses of omecamtiv mecarbil producing plasma concentrations previously shown to increase
systolic function were well tolerated during exercise in these study patients with ischemic cardiomyopathy and angina.
There was no indication that treatment increased the likelihood of myocardial ischemia in this high-risk population.
(Pharmacokinetics [PK] and Tolerability of Intravenous [IV] and Oral CK-1827452 in Patients With Ischemic Cardio-
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AB BR EV I A T I O N S
AND ACRONYM S
AE = adverse event
Cmax = maximum plasma
concentration
CPK = creatine phosphokinase
ECG = electrocardiogram
ETT = exercise treadmill test
IV = intravenous
LV = left ventricular
SAE = serious adverse event
= upper limit of normal
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23O mecamtiv mecarbil (formerly CK-1827452and AMG 423) is a selective, small moleculeactivator of cardiac myosin that binds to
the catalytic domain of myosin and increases the tran-
sition rate of myosin into the actin-bound force-gener-
ating state without affecting cardiac myocyte
intracellular calcium (1). In healthy subjects and in pa-
tients with stable heart failure, infusions of omecamtiv
mecarbil resulted in statistically signiﬁcant, dose-
related, and concentration-related increases in sys-
tolic ejection time associated with increases in indices
of left ventricular (LV) systolic function such as stroke
volume, fractional shortening, and ejection fraction
(2,3). No consistent pattern of adverse events (AEs)
was observed in patients who were tolerant of drug
infusion. In both healthy subjects and patients with
heart failure, the dose-limiting effect of omecamtiv
mecarbil was myocardial ischemia. This occurred in
some patients at plasma concentrations >1,200 ng/ml
and was likely due to excessive prolongation of the
systolic ejection time, reducing the time for coronary
perfusion during diastole. Because heart rate, coro-
nary blood ﬂow, and myocardial oxygen demand in-
crease while the overall duration of the cardiac cycle
shortens, factors that may increase susceptibility to
ischemia when systolic ejection time is increased
include coronary artery disease or exercise.
Our goalwas to understand the effects of exercise on
the safety and tolerability of omecamtiv mecarbil in a
relevant patient population as a prelude to chronic
dosing. The present study was designed to evaluate
omecamtiv mecarbil in patients with ischemic
cardiomyopathy and angina in a controlled, well-
monitored setting by using symptom-limited exercise
during intravenous (IV) infusions of omecamtiv
mecarbil. The doses of omecamtiv mecarbil were
selected to produce plasma drug concentrations asso-
ciated with increases in systolic ejection time and LV
systolic function (2). An additional goal of the study
was to obtain the ﬁrst pharmacokinetic and tolerability
data in patients with heart failure after oral dosing to
steady state.
METHODS
This double-blind, randomized, placebo-controlled
study was conducted between April 2008 and
November 2008 at 12 sites in the Republic of Georgia
and the Russian Federation. Independent ethics
committees at each study site approved the protocol,
and all patients provided written informed consent
before initiation of study-speciﬁc procedures. The
study was conducted in compliance with the Decla-
ration of Helsinki.PATIENTS. Eligible patients were adults ($18
years of age) with documented ischemic car-
diomyopathy and angina. Ischemic heart dis-
ease was deﬁned as a history of myocardial
infarction documented by elevated creatine
phosphokinase (CPK)-MB, troponin I or T, or
the presence of electrocardiographic Q waves
consistent with myocardial infarction, and/or
coronary angiography demonstrating $1 ma-
jor epicardial coronary artery with a stenosis
of $60% diameter but excluding stenosis of
the left main coronary artery unless revascu-
larized by coronary artery bypass grafting.
Patients had a history of $1 episode of exercise-
induced angina within 2 months before screening.
Patients were required to have an LV ejection
fraction #35% and an LV end-diastolic diameter $55
mm or LV end-diastolic diameter index $32 mm/m2
(conﬁrmed by the core echocardiography laboratory
before randomization); New York Heart Association
functional class II or III for $3 months before
screening; and treatment with stable standard therapy
for heart failure $4 weeks before screening. Patients
had the capacity to complete $4 min of a Modiﬁed
Naughton exercise tolerance test (ETT) (Online
Table S1) (4).
Exclusion criteria included acute myocarditis;
clinically signiﬁcant restrictive, constrictive, or hy-
pertrophic obstructive cardiomyopathy; clinically
signiﬁcant congenital heart disease; systolic blood
pressure >160 mm Hg documented on $3 occasions
separated by 10 min; levels of troponin I or T or CPK-
MB greater than the upper limit of normal (ULN)
within 6 weeks of screening and up to randomization;
severe aortic or mitral stenosis; acute coronary syn-
drome, transient ischemic attack, or revascularization
within 6 weeks of screening; signiﬁcant comorbid
conditions that would limit treadmill exercise; renal
or hepatic impairment; receipt of an investigational
drug or device within 30 days or 5 half-lives before
randomization; weight >120 kg; body temperature
>38

C; any laboratory abnormality that would pre-
clude participation in the study; or previous treat-
ment with omecamtiv mecarbil.
STUDY DESIGN. Two sequential cohorts of patients
were enrolled (Figure 1). Before randomization, pa-
tients had to complete 2 separate screening ETTs
(ETT1 and ETT2) administered at least 24 h apart,
achieving $4 min of a Modiﬁed Naughton Exercise
Protocol on both tests (Online Methods). Baseline ETT
performance was deﬁned as the shorter of the 2 ex-
ercise durations recorded during the screening ETTs.
Patients in each cohort were randomly assigned in a
2:1 ratio to receive an IV infusion of omecamtiv
ULN
FIGURE 1 Study Schema
Cmax ¼maximum plasma concentration; EOS ¼ end of study; ETT ¼ exercise tolerance test;
IV ¼ intravenous; LVEF ¼ left ventricular ejection fraction; po ¼ orally; TID ¼ 3 times daily.
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24mecarbil or placebo over 20 h. A third ETT (ETT3) was
performed during the ﬁnal 2 h of IV dosing. Patients
in the omecamtiv mecarbil arms were dosed to target
plasma levels of w295 ng/ml in cohort 1 (24 mg/h for
2 h followed by 6 mg/h for 18 h) and w550 ng/ml in
cohort 2 (48 mg/h for 2 h followed by 11 mg/h for 18 h).
Patients who tolerated the IV infusion then self-
administered omecamtiv mecarbil orally (immediate
release; 12.5 mg and 25 mg for cohorts 1 and 2,
respectively) or placebo orally 3 times daily for 7 days.
Patients had a follow-up visit 6 to 14 days after the
last oral dose. There were no exercise tests during or
after oral dosing.
In each cohort, patients were assigned to treatment
via central randomization by an independent vendor.
An unblinded site pharmacist prepared the study
medications and provided them to blinded site staff
according to the randomization system assignment.
Core laboratories were used for analysis of echo-
cardiograms (ICON Medical Imaging, Warrington,
Pennsylvania) and exercise electrocardiograms
(ECGs) (St. Louis University Core ECG Lab, St. Louis,
Missouri). Two local core laboratories were used
to analyze blood samples for cardiac enzymes
(INVITRO Central Laboratory, Moscow, Russia;
Medical Center CITO Ltd., Tbilisi, Georgia). The upper
reference limit for assays performed by Medical
Center CITO was $0.11 mg/l and for INVITRO was $ 1
mg/l; the limit of detection for Medical Center CITO
assays was 0.01 mg/l, and it was not speciﬁed for the
INVITRO assays.STUDY ENDPOINTS. The primary endpoint of this
safety study was the proportion of patients who
stopped ETT3 because of angina and at a stage earlier
than baseline. Secondary safety endpoints included
the proportion of patients who stopped ETT3 for any
reason at a stage earlier than baseline; duration of
exercise during ETT3; proportion of patients with
angina during ETT3; time to angina during ETT3;
proportion of patients with 1-mm ST-segment
depression on their ECG during ETT3; time to 1-mm
ST-segment depression during ETT3; and AEs and
serious adverse events (SAEs).
Secondary objectives were the assessment of
tolerability and steady-state omecamtiv mecarbil
plasma concentrations at trough and 1 h after dosing
3 times daily for 7 days with an immediate-release,
blend-in-capsule oral formulation.
STATISTICAL ANALYSIS. Sample size was empiri-
cally determined to provide an adequate assessment
of tolerability. Patients who received placebo in both
cohorts were pooled for this analysis. For change
in duration of exercise between baseline and ETT3,
the comparison between patients who received
omecamtiv mecarbil and patients who received pla-
cebo was performed by using an analysis of covari-
ance model, with treatment group as the main effect
and baseline ETT exercise duration as a covariate. For
categorical variables, treatment differences in pro-
portion with 95% conﬁdence intervals between
omecamtiv mecarbil and placebo were constructed by
using the Meittinen-Nurminen approach. For the time
to angina and time to 1-mm ST-segment depression
during ETT3, survival analysis techniques were used.
The log-rank test was used to test the equality of
time to onset of 1-mm ST-segment depression and
time to onset of angina between omecamtiv mecarbil
and placebo. Pharmacokinetic analyses according
to standard noncompartmental methods were per-
formed by using WinNonlin Professional (Pharsight,
St. Louis, Missouri). Treatment-emergent AEs and
SAEs occurring from the ﬁrst dose through 30 days
after the last dose were summarized and coded by
using the Medical Dictionary for Regulatory Activities
version 10.1. Statistical analyses were performed by
using SAS version 9.1.3 (SAS Institute, Inc., Cary,
North Carolina).
The safety population represented all patients who
were randomized to a treatment group and received
any study drug. The safety ETT population comprised
all patients in the safety population who received any
study drug and performed ETT3. The pharmacoki-
netics population included patients in the safety
population who had $1 measurable plasma sample for
pharmacokinetics testing and no protocol violations
TABLE 1 Patient Demographic and Clinical Characteristics at Baseline
(Safety Population)
Placebo
(n ¼ 29)
Omecamtiv Mecarbil
All Patients
(N ¼ 94)
Cohort 1*
(n ¼ 31)
Cohort 2†
(n ¼ 34)
Age, yrs
Mean  SD 62.3  9.8 65.2  10.0 62.6  8.1 63.4  9.3
Range 42–80 40–79 46–76 40–80
Male 23 (79.3) 23 (74.2) 29 (85.3) 75 (79.8)
Weight, kg 80.0  11.9 78.7  10.8 78.5  14.1 79.0  12.3
BMI, kg/m2 26.5  3.4 26.3  3.4 26.8  4.1 26.5  3.6
White race 29 (100) 31 (100) 34 (100) 94 (100)
Primary ischemic etiology 29 (100) 31 (100) 34 (100) 94 (100)
Previous MI 21 (72.4) 21 (67.7) 30 (88.2) 72 (76.6)
Smoking history
Current 6 (20.7) 5 (16.1) 9 (26.5) 20 (21.3)
Never 11 (37.9) 14 (45.2) 13 (38.2) 38 (40.4)
Quit <6 months 1 (3.4) 1 (3.2) 1 (2.9) 3 (3.2)
Quit $6 months 11 (37.9) 11 (35.5) 11 (32.4) 33 (35.1)
SBP, mm Hg 120  10 120  11 122  13 121  11
Heart rate, beats/min 74.3  12.7 73.5  16.1 69.4  12.5 72.3  13.9
Rales present 9 (31.0) 13 (41.9) 12 (35.2) 34 (36.2)
Peripheral edema
0 15 (51.7) 15 (48.4) 21 (61.8) 51 (54.3)
1þ 3 (10.3) 2 (6.5) 6 (17.6) 11 (11.7)
2þ 8 (27.6) 11 (35.5) 5 (14.7) 24 (25.5)
3þ 3 (10.3) 3 (9.7) 2 (5.9) 8 (8.5)
LVDD, cm
Mean  SD 7.2  0.7 7.1  1.1 7.2  0.9 7.1  0.9
Range 5.1–8.7 5.2–10.3 5.5–9.2 5.1–10.3
LVEF, % 23 (6) 22 (7) 21 (7) 22 (7)
Medical therapy
ACEI/ARB 29 (100) 31 (100) 34 (100) 94 (100)
Beta-blocker 29 (100) 31 (100) 34 (100) 94 (100)
Spironolactone 26 (89.7) 28 (90.3) 26 (76.5) 80 (85.1)
Digoxin 5 (17.2) 9 (29.0) 7 (20.6) 21 (22.3)
Baseline ETT‡ exercise duration, s
Mean  SD 380  121 377  124 369  112 375  118
Range 300–720 300–900 300–720 300–900
Stopped ETT-1 or ETT-2
for angina
4 (13.8) 0 7 (20.6) 11 (11.7)
ECG assessable for 1-mm
ST-segment depression
10 (34.5) 8 (25.8) 12 (35.4) 30 (31.9)
Patients with 1-mm ST-segment
depression during ETT-1
2 (20.0) 0 (0.0) 1 (8.3) 3 (10.0)
Values are mean  SD, range, or n (%). *Cohort 1: Omecamtiv mecarbil infused at 24 mg/h for 2 h followed by 6
mg/h for 18 h. Patients who tolerated the infusion then received omecamtiv mecarbil 12.5 mg orally 3 times daily
for 7 days. †Cohort 2: Omecamtiv mecarbil infused at 48 mg/h for 2 h followed by 11 mg/h for 18 h. Patients who
tolerated the infusion then received omecamtiv mecarbil 25 mg orally 3 times daily for 7 days. ‡Baseline ETT was
the shorter of the screening ETTs (ETT1 or ETT2).
ACEI ¼ angiotensin-converting enzyme inhibitor; ARB ¼ angiotensin II receptor blocker; BMI ¼ body mass
index; ETT ¼ exercise tolerance test; LVDD ¼ left ventricular end-diastolic dimension; LVEF ¼ left ventricular
ejection fraction; MI ¼ myocardial infarction; SBP ¼ systolic blood pressure.
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25that could have affected the pharmacokinetics of
omecamtiv mecarbil.
RESULTS
PATIENTS. A total of 95 patients were randomized
to treatment, and 1 patient withdrew from the study
because of inﬂuenza just before dosing. Of the 94
patients who received the study drug, 46 were
allocated to cohort 1 (31 omecamtiv mecarbil;
15 placebo) and 48 were allocated to cohort 2 (34
omecamtiv mecarbil; 14 placebo) (Online Figure S1).
All patients in cohort 1 completed IV dosing, and
only 1 patient did not complete oral dosing (ome-
camtiv mecarbil arm). The patient who discontinued
omecamtiv mecarbil in cohort 1 had an asymptom-
atic elevated CPK-MB level (36 U/l; ULN 24 U/l);
troponin I was undetectable at the coincident time
point and all other time points. All patients in cohort
2 completed IV dosing, and 3 patients did not com-
plete oral dosing (omecamtiv mecarbil arm). Of
these, 1 patient had an SAE (described in the
following discussion); 1 patient had troponin levels
of 1.1 ng/ml (ULN 1.0 ng/ml) after ETT3 in the
absence of other speciﬁc clinical signs or symptoms
of cardiac ischemia; and 1 patient had asymptomatic
elevated CPK-MB (6.4 ng/ml; ULN 5.8 ng/ml;
troponin I was undetectable at the coincident time
point and all other time points).
Baseline demographic and clinical characteristics
were similar among patients receiving placebo or
omecamtiv mecarbil (Table 1, Online Table S2). All
patients were white, and most (80%) were men; their
mean age was 63.4 years. Eleven patients (11.7%)
stopped one of the baseline exercise tests conducted
before study drug infusion (ETT1 or ETT2) because of
angina (none in cohort 1; 4 on placebo; 7 on ome-
camtiv mecarbil in cohort 2).
PRIMARY AND SECONDARY SAFETY ENDPOINTS. In
the placebo arm, 1 patient (3.4%) stopped ETT3
(during infusion) at a stage earlier than baseline
because of angina while none did so in the omecamtiv
mecarbil arm at either dose (Table 2, Online Table S3).
Seven patients (1 taking placebo; 4 taking ome-
camtiv mecarbil in cohort 1; 2 taking omecamtiv
mecarbil in cohort 2) stopped ETT3 for any reason at a
stage earlier than baseline (Table 2). The differences
in the proportions of patients who stopped ETT3 for
any reason at a stage earlier than baseline between
patients receiving omecamtiv mecarbil and those
receiving placebo (treatment difference in proportion
[95% conﬁdence intervals] for cohort 1: 9.5% [–6.2 to
26.2]; cohort 2: 2.4% [–12.2 to 16.4]) were not statis-
tically signiﬁcant. The most common reason forstopping ETT3 at a stage earlier than baseline was
limiting fatigue.
There were 9 patients who also stopped at least
one of the baseline ETTs (ETT1 and/or ETT2) because
of angina; 7 of these 9 patients stopped both baseline
ETTs because of angina. During ETT3, the same 9
TABLE 2 Safety Endpoints Summary (Safety ETT Population)
Placebo
(n ¼ 29)
Omecamtiv Mecarbil
Cohort 1*
(n ¼ 31)
Cohort 2†
(n ¼ 34)
Primary endpoint
Patients who stopped ETT3 for angina
at stage earlier than baseline
1 (3.4) 0 (0.0) 0 (0.0)
Secondary endpoints
Patients who stopped ETT3 for any reason
at stage earlier than baseline
1 (3.4) 4 (12.9) 2 (5.9)
Patients who stopped ETT3 for angina 2 (6.9) 0 (0.0) 7 (20.6)
Time to angina during ETT3, s 325.5  123.7 NA 345.9  69.4
Change from baseline ETT in exercise
duration during ETT3, s
60.1  71.2 41.5  113.1 40.5  70.6
Patients with 1-mm ST-segment
depression during ETT3, n/N
assessable‡ (%)
2/7 (28.6) 0/10 (0.0) 1/12 (8.3)
Time to 1-mm ST-segment
depression, s
300, 620§ NA 235k
Values are n (%) or mean  SD. *Cohort 1: Omecamtiv mecarbil infused at 24 mg/h for 2 h followed by
6 mg/h for 18 h. Patients who tolerated the infusion then received omecamtiv mecarbil 12.5 mg orally 3 times
daily for 7 days. †Cohort 2: Omecamtiv mecarbil infused at 48 mg/h for 2 h followed by 11 mg/h for 18 h. Patients
who tolerated the infusion then received omecamtiv mecarbil 25 mg orally 3 times daily for 7 days. ‡Patients
were not considered to have electrocardiographs interpretable for ST-segment analysis if they had baseline ST-
segment depression$1 mm, left bundle branch block or right bundle branch block, or ventricular pacing or if they
were receiving digoxin. §Values for 2 patients with 1-mm ST-segment depression during ETT-3. kValue for 1
patient with 1-mm ST-segment depression during ETT-3.
NA ¼ not applicable; other abbreviation as in Table 1.
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26patients (2 in the placebo group; 7 in the omecamtiv
mecarbil group in cohort 2) stopped again because of
angina (Table 2). In 3 of these 9 patients, the dura-
tion of ETT3 was shorter than the baseline ETT
(1 patient in the placebo group; 2 in the omecamtiv
mecarbil group in cohort 2). The exercise stage at
which each of these 9 patients stopped ETT3 was the
same stage at which their baseline ETT was stopped,
and hence they did not contribute to the primary
endpoint.
Exercise time during ETT3 compared with baseline
increased in all treatment groups (Table 2). Although
the overall increase in exercise time was greater with
placebo than with omecamtiv mecarbil in each of
cohorts 1 and 2, the difference was not statistically
signiﬁcant, and the increase in exercise time was
similar for both dose levels of omecamtiv mecarbil. A
greater proportion of patients exercised to stage 4 or
above during ETT3 compared with ETT1 or ETT2
across all treatment groups (Figure 2).
Patients with heart failure due to ischemic cardio-
myopathy frequently had reasons that precluded
interpretation of exercise-induced ischemia on their
ECG (e.g., resting ST-segment depression, left bundle
branch block, treatment with digoxin) (5). Of the 94
patients, 29 had ECGs interpretable for ST-segment
analysis; exclusions included those who were
receiving digoxin and those who had baseline ST-segment depression $1 mm, left bundle branch
block or right bundle branch block, or ventricular
pacing. Of these 29 patients, only 2 patients receiving
placebo and 1 patient receiving omecamtiv mecarbil
in cohort 2 had $1-mm ST-segment depression during
ETT3. In the 1 patient taking omecamtiv mecarbil,
time to the onset of 1-mm ST-segment depression
during ETT3 (235 s) was somewhat shorter than ETT2
(311 s), which was new compared with ETT1 when the
patient did not have ST-segment depression.
TREATMENT-EMERGENT AEs. Nineteen patients
(20.2%) experienced 29 distinct treatment-emergent
AEs (Table 3), including 17.2% on placebo, a 6.5%
on omecamtiv mecarbil in cohort 1, and 35.3% on
omecamtiv mecarbil in cohort 2. Of the 29 distinct
AEs, 23 events were reported as mild in severity, 4 as
moderate, and 2 as serious/severe (both occurring in
the same patient [as discussed in the following
section]). The investigators assessed 14 of the 29
AEs as not related to treatment, 8 of the 29 as
possibly related to treatment, and 7 of the 29 as
probably related to treatment. The majority of the
AEs occurred during the infusion phase; in the oral
dosing phase, only 4 AEs were reported (2 in patients
on placebo and 2 in patients on omecamtiv mecarbil).
Although AEs were more frequent in cohort 2 for
patients on omecamtiv mecarbil, in all but 2 patients
they were mild in severity (1 patient with moderate
photopsia and 1 patient described in the following
section in more detail) and there was no consistent
pattern in the types of AEs reported (Table 3, Online
Table S4). All AEs had resolved by the end of the
study.
Two SAEs were reported in 1 patient receiving
omecamtiv mecarbil in cohort 2. After tolerating 18 h
of omecamtiv mecarbil infusion without issue, in the
last 2 h of the infusion, the patient underwent his
third exercise test. He terminated ETT3 because of
intolerable angina and ST-segment depression, which
he also experienced during ETT2. The patient
received nitroglycerin during the recovery period of
ETT3, during which his symptoms resolved; he sub-
sequently underwent coronary stent implantation
for a severe proximal lesion in the left anterior
descending artery. After stent implantation, the pa-
tient had a peak troponin I level of 2.45 ng/ml.
The maximum plasma concentration of omecamtiv
mecarbil for this patient was 651 ng/ml. The investi-
gator reported SAEs of acute coronary syndrome and
non–Q-wave myocardial infarction associated with
percutaneous transluminal coronary angioplasty. The
patient was discontinued from the study.
No clinically meaningful changes in vital signs
(systolic blood pressure/diastolic blood pressure,
FIGURE 2 Percentage of Patients Achieving Each Stage of the Modiﬁed Naughton
ETT at Baseline and on Blinded Study Drug Treatment During ETT3
The highest stage achieved for 2 symptom-limited exercise treadmill tests (ETTs) at
baseline (ETT1 and ETT2) and ETT3 after treatment for patients receiving (A) placebo,
(B) omecamtiv mecarbil in cohort 1, and (C) omecamtiv mecarbil in cohort 2 are shown.
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27heart rate, respiratory rate, and oxygen saturation) or
cardiac enzymes (troponin I, CPK-MB, and total cre-
atine kinase) for any of the treatment groups were
observed. Systolic blood pressure and heart rate data
throughout the study are shown in Online Tables S5
and S6. Overall, few patients had detectable or
elevated levels of troponin I (Online Table S7) or CPK-
MB above the ULN (Online Table S8) at any time
during the study. Before study drug infusion, 1 pa-
tient in the placebo group and 1 patient in cohort 1
had detectable or elevated troponin I levels at
screening, and 1 patient in the placebo group had
detectable or elevated troponin I levels before and
after ETT1. Two patients taking omecamtiv mecarbil
had troponin I results that were just above the ULN
after study drug infusion following ETT3: peak
troponin I levels were 0.13 mg/l (ULN <0.11 mg/l) for a
patient in cohort 1 and 1.1 mg/l (ULN <1.0 mg/l) for a
patient in cohort 2. There were no other clinical signs
or symptoms of ischemia in these 2 patients.
PHARMACOKINETICS. Mean plasma concentrations
of omecamtiv mecarbil at 20 h after IV dosing were
283 ng/ml for cohort 1 and 575 ng/ml for cohort 2,
consistent with the predicted values (295 ng/ml and
550 ng/ml for cohorts 1 and 2, respectively) derived by
using pharmacokinetic parameters from healthy vol-
unteers (3). Increases in mean maximum plasma
concentration (Cmax) and area under the plasma
concentration–time curve from time 0 to the time of
last quantiﬁable plasma concentration values from
cohort 1 to cohort 2 were modestly higher than pre-
dicted from a strictly dose-proportional increase;
Cmax levels were 344  265 ng/ml and 708  268 ng/ml
in cohorts 1 and 2, respectively. Time to Cmax was
similar between doses (Table 4). Mean plasma con-
centrations 1 h after the last oral dose were 74 ng/ml
for cohort 1 and 208 ng/ml for cohort 2.
DISCUSSION
Increasing cardiac contractility would seem to be a
rational approach to treating patients with systolic
heart failure. However, inotropic drugs increase the
risk of ischemia, arrhythmias, and death, and this risk
has limited their utility in treating acute and chronic
heart failure (6–10). Currently available inotropic
drugs increase cardiac contractility indirectly by
increasing cardiac myocyte intracellular calcium con-
centration (11). Another approach to increasing cardiac
contractility by directly activating the sarcomere with
a cardiac myosin activator may overcome the limita-
tions of the currently available inotropic drugs (12).
Omecamtiv mecarbil is a novel, direct cardiac
myosin activator that increases cardiac contractilityand may become an important therapy for heart
failure patients with systolic dysfunction. The echo-
cardiographic hallmark for the pharmacodynamic
activity of omecamtiv mecarbil is an increase in the
systolic ejection time that is highly correlated with
omecamtiv mecarbil plasma concentration (2,3).
Because the majority of coronary blood ﬂow occurs
during diastole, this effect of omecamtiv mecarbil
could reduce the time for myocardial perfusion. Thus,
it was critical to evaluate omecamtiv mecarbil in pa-
tients with ischemic cardiomyopathy and angina
during exercise in a well-controlled and monitored
setting.
The present study was designed to provide an
indication of the safety and tolerability of omecamtiv
mecarbil in ambulatory patients with chronic heart
TABLE 3 Treatment-Emergent AEs (Safety Population)
Placebo
(n ¼ 29)
Omecamtiv Mecarbil
All Patients
(N ¼ 94)
Cohort 1*
(n ¼ 31)
Cohort 2†
(n ¼ 34)
Patients with $1 AE 5 (17.2) 2 (6.5) 12 (35.3) 19 (20.2)
Mild 3 (10.3) 2 (6.5) 11 (32.4) 16 (17.0)
Moderate 2 (6.9) 1 (3.2) 1 (2.9) 4 (4.3)
Severe 0 0 1 (2.9) 1 (1.1)
AEs
Acute coronary syndrome 0 0 1 (2.9) 1 (1.1)
Increased blood CPK-MB 0 0 1 (2.9) 1 (1.1)
Increased cardiac enzyme 0 0 1 (2.9) 1 (1.1)
Dizziness 0 0 1 (2.9) 1 (1.1)
Dyspnea 1 (3.4) 0 3 (8.8) 4 (4.3)
Gout 0 0 1 (2.9) 1 (1.1)
Headache 1 (3.4) 0 0 1 (1.1)
Hypertension 0 0 1 (2.9) 1 (1.1)
Hypotension 0 1 (3.2) 1 (2.9) 2 (2.1)
Infusion site erythema 0 1 (3.2) 0 1 (1.1)
Infusion site pain 1 (3.4) 1 (3.2) 0 2 (2.1)
Photopsia 1 (3.4) 0 1 (2.9) 2 (2.1)
Post-procedural myocardial
infarction
0 0 1 (2.9) 1 (1.1)
Pyrexia 1 (3.4) 0 0 1 (1.1)
Rhinitis 0 0 1 (2.9) 1 (1.1)
Sinus bradycardia 0 0 1 (2.9) 1 (1.1)
Supraventricular tachycardia 0 0 1 (2.9) 1 (1.1)
Increased troponin I 0 0 1 (2.9) 1 (1.1)
Upper abdominal pain 0 1 (3.2) 0 1 (1.1)
Ventricular extrasystoles 0 0 2 (5.9) 2 (2.1)
Values are n (%). *Cohort 1: Omecamtiv mecarbil infused at 24 mg/h for 2 h followed by 6 mg/h
for 18 h. Patients who tolerated the infusion then received omecamtiv mecarbil 12.5 mg orally 3
times daily for 7 days. †Cohort 2: Omecamtiv mecarbil infused at 48 mg/h for 2 h followed by 11
mg/h for 18 h. Patients who tolerated the infusion then received omecamtiv mecarbil 25 mg orally
3 times daily for 7 days.
AE ¼ adverse event; CPK ¼ creatine phosphokinase.
TABLE 4 Pharmacokinetic Parameters After IV Dosing
(PK Population)
Omecamtiv Mecarbil
Cohort 1*
(n ¼ 26)
Cohort 2†
(n ¼ 30)
Cmax, ng/ml 344  265 708  268
Tmax, h 13.6  8.6 15.7  6.4
AUClast, h  ng/ml 7,800  3,400 18,400  6,700
Values are mean  SD. *Cohort 1: Omecamtiv mecarbil infused at 24 mg/h for 2 h
followed by 6 mg/h for 18 h. †Cohort 2: Omecamtiv mecarbil infused at 48 mg/h
for 2 h followed by 11 mg/h for 18 h.
AUClast ¼ area under the plasma concentration–time curve from time 0 to the
time of last quantiﬁable plasma concentration; Cmax ¼ maximum plasma concen-
tration; IV ¼ intravenous; Tmax ¼ time to maximum plasma concentration.
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28failure before embarking on larger and longer studies
that would more deﬁnitively assess the risk/beneﬁt
proﬁle of this agent. The results of this study showed
that in patients who theoretically would be most
vulnerable to prolongation of the systolic ejection
time (i.e., those with ischemic cardiomyopathy and a
history of angina), treatment with omecamtiv
mecarbil had no substantial deleterious effects on a
broad range of safety assessments in the setting of
symptom-limited exercise. Potential measures of
cardiac ischemia such as the primary endpoint of this
study (i.e., the proportion of patients who stopped
ETT3 because of angina and at a stage earlier than
baseline) and the time to or appearance of ST-
segment depression (which were assessable on ECG)
were not adversely affected. Exercise time was also
not adversely affected. This study was neither spe-
ciﬁcally designed nor powered to detect a potentially
clinically signiﬁcant improvement in exerciseperformance. Given the average baseline exercise
time and variability in this study, it would have
required >3 times the number of patients per treat-
ment arm than were actually enrolled to detect a 15%
improvement in exercise time (80% power with a
2-sided alpha at 0.05). Finally, there were no consis-
tent dose-related changes in the AE proﬁle, and the
majority of AEs were mild in severity.
Troponin I levels were abnormal in 2 patients after
exercise; in each case, the levels were just above the
upper laboratory reference limit and occurred in the
absence of other clinical signs or symptoms of cardiac
ischemia. The background rate of detectable troponin
after exercise testing in this patient population is
not well established, but was approximately 10% in 2
small studies (13,14). Given the number of patients
studied, our ﬁndings do not rule out the possibility
that increases in troponin I might occur in some heart
failure patients with coronary disease during exercise
while receiving omecamtiv mecarbil treatment, but
they do indicate that the occurrence of this event is
likely to be low. The use of a high-sensitivity troponin
assay in this study might have provided additional
insights into the development of ischemia in this
population during exercise.
STUDY LIMITATIONS. Although the present study
provides the ﬁrst evaluation of omecamtiv mecarbil
in heart failure patients under nonsedentary con-
ditions, it has some important limitations. No
hypothesis was formally tested, and the sample size
was therefore empirically determined to be sufﬁcient
to provide an adequate assessment of the tolerability
of the 2 target omecamtiv mecarbil plasma levels
during symptom-limited exercise tolerance in pa-
tients with ischemic cardiomyopathy and angina.
In addition, the sample size was too small to assess
the effect on exercise time, and thus either a posi-
tive or negative effect on exercise duration could
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29not be established. The study did not formally assess
the effect of omecamtiv mecarbil on inducible
ischemia or chest pain, and the angina burden of the
study population was not thoroughly characterized.
The majority of ECGs in the enrolled population
were noninterpretable for ischemia, which is
common in patients with heart failure, and only a
minority had angina while performing exercise in
this study. Conﬁning enrollment to heart failure
patients with evidence of reproducible exercise-
induced ischemia on ECG and/or exercise-limiting
angina while at the same time increasing the
sample size to assess the question of exercise
capacity would have made execution of the study
unfeasible, however (15). A limitation of the present
study is that the troponin assays used at the time of
this study did not meet current standards for
troponin assays as required for the diagnosis of
myocardial infarction.
The present study supports the conclusion that
omecamtiv mecarbil did not increase the likelihood of
myocardial ischemia in patients with ischemic car-
diomyopathy and angina and serves as a prelude to
the chronic dosing of omecamtiv mecarbil in ambu-
latory patients with chronic heart failure. Nonethe-
less, vigilance is warranted as the drug is tested in
larger populations of patients that include those withunderlying coronary disease. Results of this study,
together with previous studies evaluating the phar-
macodynamic effects of omecamtiv mecarbil in
healthy volunteers and patients with stable heart
failure (2,3), support further clinical assessment of
omecamtiv mecarbil in patients with acute and
chronic heart failure. A Phase II trial ofw600 patients
with acute heart failure and LV dysfunction who
received omecamtiv mecarbil IV was recently
completed (NCT01300013). Oral formulations of
omecamtiv mecarbil are currently under evaluation
to enable the assessment of the potential beneﬁts of
omecamtiv mecarbil related to symptoms, quality of
life, exercise capacity, morbidity, and mortality in
larger and longer clinical trials.
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